Aevi Genomic Medicine (NASDAQ:GNMX) Trading Up 16.7%

Aevi Genomic Medicine Inc (NASDAQ:GNMX)’s stock price was up 16.7% on Tuesday . The company traded as high as $0.23 and last traded at $0.21, approximately 4,345,140 shares were traded during trading. An increase of 99% from the average daily volume of 2,183,438 shares. The stock had previously closed at $0.18.

Separately, ValuEngine raised Aevi Genomic Medicine from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The stock has a 50-day moving average of $0.18. The stock has a market capitalization of $13.60 million, a PE ratio of -0.42 and a beta of 0.73.

Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, research analysts expect that Aevi Genomic Medicine Inc will post -0.27 EPS for the current year.

A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Virtu Financial LLC boosted its holdings in Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 675.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 278,958 shares of the biotechnology company’s stock after acquiring an additional 242,994 shares during the period. Virtu Financial LLC owned 0.43% of Aevi Genomic Medicine worth $55,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.45% of the company’s stock.

About Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Recommended Story: What is the definition of a trade war?

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.